2026 Q1 -tulosraportti
61 päivää sitten
‧1 t 1 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sitten · MuokattuQ2 report is on August 6. I don't know how Immunovia thinks. But wouldn't it be a bit embarrassing not to have any news before then? Of course, that date will be a relevant day to have some news. But that they are almost constantly forced to churn out some explanations and/or news around quarterly figures - I hope that trend can be broken soon. Mid-2026 is June/July and actually not in August. Despite it also being a bit close to the middle. How difficult is it, Jeff, to submit a Medicare application?
I don't think that "mid-2026" is set in stone. In the report and the latest presentation, they probably talk about "2026" (previously it was H1 2026). Actually, it's probably better if they wait, because they have no meaningful utility data to get it approved anyway.
·1 päivä sittenA thought.. according to Jeff, after Q1 they had cash that lasts 2-3 quarters IF they don't increase revenues and/or secure a partnership agreement. I find it hard to believe they have significantly increased revenues and we haven't heard anything about any potential partnership. Based on this, I assume/guess that they will initiate yet another new share issue in connection with the Q2 report in August... Interested in your view on this.Based on how it has looked previously, they usually postpone it as long as possible. They probably have capital until Q3 at least, certainly a bit into Q4. With a bit of bridge loan on top of that, maybe it can be postponed until October at least. As I said, I don't believe in partners as financing. Why lend out 100 MSEK at high risk, when you can buy the whole company for the same amount? Partners have a role in accelerating sales, I don't think it's much more than that. A rich investor who injects money is worse than a new share issue, because then it becomes a dilution where existing shareholders cannot participate and defend themselves. Then I believe more in acquisitions, but it's not the right time for that yet.- ·1 päivä sitten · MuokattuI am quoting Krosen on the Placera forum. @Micketro (this is Krosen) My question to Micketro. Quote further down. Immunovia must be reasonably confident in itself by letting her leave the job. Alternatively, she has probably been looking for a suitable job. But one can always try to negotiate with both parties about compensation and transition. In any case, Immunovia must now manage without her. Quote: "Norma Palma has left We discussed it as a possibility when they announced they were looking for a new person for her previous role, but now it's official that she has moved on to another employer. Norma is the one who has driven all studies for the updated test, and now it's up to her successor to drive the clinical study work." https://forum.placera.se/inlagg/31b8cf1e-1d71-4b7e-9e61-242d214c596cNo problem, they will do fine. It doesn't seem like she usually stays much longer than 2 years with her employers. Still, I think it's important news to inform about- she has been the most important person in the entire company until now.
- ·1 päivä sitten · MuokattuJuly 6 and no news. Either it happens any moment now or Immunovia is behind schedule? So what will it be? Immunovia cannot really influence the New York decision much, other than providing the necessary data. Medicare, on the other hand, was said to be mid-2026, which is now. They just need to package it nicely and submit it.
- ·3 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54 On the Placera forum, a small debate is ongoing where BoBoKrull is not wrong. But a challenging question is posed. Thread starter Sado naturally means the obvious. That the Medicare application is imminent if one is to believe the Immunovia management. A news item is awaited that the application will be submitted, and that will be a nice milestone in itself. That should give the stock a small boost or perhaps a larger one. It is not meant that Medicare will give approval anytime soon, because it is a lengthy process. It is more lengthy there at Medicare than at New York, which can approve à la California-level anytime. Getting New York approved will provide a complete 50-state approval, and both these news items will make PancreaSure more attractive for a potential further partner discussion. And both these news items should, if (!) one can trust Immunovia management, happen now this summer. NY should have happened last month in June, but it has not happened. Medicare application submission was promised mid-2026, which we are at now. The ASSURE study is in place, and they will have ongoing updates on the study to Medicare, which was the plan we have been presented with. https://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
61 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuQ2 report is on August 6. I don't know how Immunovia thinks. But wouldn't it be a bit embarrassing not to have any news before then? Of course, that date will be a relevant day to have some news. But that they are almost constantly forced to churn out some explanations and/or news around quarterly figures - I hope that trend can be broken soon. Mid-2026 is June/July and actually not in August. Despite it also being a bit close to the middle. How difficult is it, Jeff, to submit a Medicare application?I don't think that "mid-2026" is set in stone. In the report and the latest presentation, they probably talk about "2026" (previously it was H1 2026). Actually, it's probably better if they wait, because they have no meaningful utility data to get it approved anyway.
- ·1 päivä sittenA thought.. according to Jeff, after Q1 they had cash that lasts 2-3 quarters IF they don't increase revenues and/or secure a partnership agreement. I find it hard to believe they have significantly increased revenues and we haven't heard anything about any potential partnership. Based on this, I assume/guess that they will initiate yet another new share issue in connection with the Q2 report in August... Interested in your view on this.Based on how it has looked previously, they usually postpone it as long as possible. They probably have capital until Q3 at least, certainly a bit into Q4. With a bit of bridge loan on top of that, maybe it can be postponed until October at least. As I said, I don't believe in partners as financing. Why lend out 100 MSEK at high risk, when you can buy the whole company for the same amount? Partners have a role in accelerating sales, I don't think it's much more than that. A rich investor who injects money is worse than a new share issue, because then it becomes a dilution where existing shareholders cannot participate and defend themselves. Then I believe more in acquisitions, but it's not the right time for that yet.
- ·1 päivä sitten · MuokattuI am quoting Krosen on the Placera forum. @Micketro (this is Krosen) My question to Micketro. Quote further down. Immunovia must be reasonably confident in itself by letting her leave the job. Alternatively, she has probably been looking for a suitable job. But one can always try to negotiate with both parties about compensation and transition. In any case, Immunovia must now manage without her. Quote: "Norma Palma has left We discussed it as a possibility when they announced they were looking for a new person for her previous role, but now it's official that she has moved on to another employer. Norma is the one who has driven all studies for the updated test, and now it's up to her successor to drive the clinical study work." https://forum.placera.se/inlagg/31b8cf1e-1d71-4b7e-9e61-242d214c596cNo problem, they will do fine. It doesn't seem like she usually stays much longer than 2 years with her employers. Still, I think it's important news to inform about- she has been the most important person in the entire company until now.
- ·1 päivä sitten · MuokattuJuly 6 and no news. Either it happens any moment now or Immunovia is behind schedule? So what will it be? Immunovia cannot really influence the New York decision much, other than providing the necessary data. Medicare, on the other hand, was said to be mid-2026, which is now. They just need to package it nicely and submit it.
- ·3 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54 On the Placera forum, a small debate is ongoing where BoBoKrull is not wrong. But a challenging question is posed. Thread starter Sado naturally means the obvious. That the Medicare application is imminent if one is to believe the Immunovia management. A news item is awaited that the application will be submitted, and that will be a nice milestone in itself. That should give the stock a small boost or perhaps a larger one. It is not meant that Medicare will give approval anytime soon, because it is a lengthy process. It is more lengthy there at Medicare than at New York, which can approve à la California-level anytime. Getting New York approved will provide a complete 50-state approval, and both these news items will make PancreaSure more attractive for a potential further partner discussion. And both these news items should, if (!) one can trust Immunovia management, happen now this summer. NY should have happened last month in June, but it has not happened. Medicare application submission was promised mid-2026, which we are at now. The ASSURE study is in place, and they will have ongoing updates on the study to Medicare, which was the plan we have been presented with. https://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
61 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuQ2 report is on August 6. I don't know how Immunovia thinks. But wouldn't it be a bit embarrassing not to have any news before then? Of course, that date will be a relevant day to have some news. But that they are almost constantly forced to churn out some explanations and/or news around quarterly figures - I hope that trend can be broken soon. Mid-2026 is June/July and actually not in August. Despite it also being a bit close to the middle. How difficult is it, Jeff, to submit a Medicare application?I don't think that "mid-2026" is set in stone. In the report and the latest presentation, they probably talk about "2026" (previously it was H1 2026). Actually, it's probably better if they wait, because they have no meaningful utility data to get it approved anyway.
- ·1 päivä sittenA thought.. according to Jeff, after Q1 they had cash that lasts 2-3 quarters IF they don't increase revenues and/or secure a partnership agreement. I find it hard to believe they have significantly increased revenues and we haven't heard anything about any potential partnership. Based on this, I assume/guess that they will initiate yet another new share issue in connection with the Q2 report in August... Interested in your view on this.Based on how it has looked previously, they usually postpone it as long as possible. They probably have capital until Q3 at least, certainly a bit into Q4. With a bit of bridge loan on top of that, maybe it can be postponed until October at least. As I said, I don't believe in partners as financing. Why lend out 100 MSEK at high risk, when you can buy the whole company for the same amount? Partners have a role in accelerating sales, I don't think it's much more than that. A rich investor who injects money is worse than a new share issue, because then it becomes a dilution where existing shareholders cannot participate and defend themselves. Then I believe more in acquisitions, but it's not the right time for that yet.
- ·1 päivä sitten · MuokattuI am quoting Krosen on the Placera forum. @Micketro (this is Krosen) My question to Micketro. Quote further down. Immunovia must be reasonably confident in itself by letting her leave the job. Alternatively, she has probably been looking for a suitable job. But one can always try to negotiate with both parties about compensation and transition. In any case, Immunovia must now manage without her. Quote: "Norma Palma has left We discussed it as a possibility when they announced they were looking for a new person for her previous role, but now it's official that she has moved on to another employer. Norma is the one who has driven all studies for the updated test, and now it's up to her successor to drive the clinical study work." https://forum.placera.se/inlagg/31b8cf1e-1d71-4b7e-9e61-242d214c596cNo problem, they will do fine. It doesn't seem like she usually stays much longer than 2 years with her employers. Still, I think it's important news to inform about- she has been the most important person in the entire company until now.
- ·1 päivä sitten · MuokattuJuly 6 and no news. Either it happens any moment now or Immunovia is behind schedule? So what will it be? Immunovia cannot really influence the New York decision much, other than providing the necessary data. Medicare, on the other hand, was said to be mid-2026, which is now. They just need to package it nicely and submit it.
- ·3 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54 On the Placera forum, a small debate is ongoing where BoBoKrull is not wrong. But a challenging question is posed. Thread starter Sado naturally means the obvious. That the Medicare application is imminent if one is to believe the Immunovia management. A news item is awaited that the application will be submitted, and that will be a nice milestone in itself. That should give the stock a small boost or perhaps a larger one. It is not meant that Medicare will give approval anytime soon, because it is a lengthy process. It is more lengthy there at Medicare than at New York, which can approve à la California-level anytime. Getting New York approved will provide a complete 50-state approval, and both these news items will make PancreaSure more attractive for a potential further partner discussion. And both these news items should, if (!) one can trust Immunovia management, happen now this summer. NY should have happened last month in June, but it has not happened. Medicare application submission was promised mid-2026, which we are at now. The ASSURE study is in place, and they will have ongoing updates on the study to Medicare, which was the plan we have been presented with. https://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt